Predicted protein targets (top 15)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | TSHR | P16473 | 1/20 | 0.49 |
| ▸ | NISCH | Q9Y2I1 | 1/20 | 0.41 |
| ▸ | CASP1 | P29466 | 1/20 | 0.41 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.39 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.39 |
| ▸ | HTR2A | P28223 | 2/20 | 0.39 |
| ▸ | SLC6A4 | P31645 | 2/20 | 0.39 |
| ▸ | KCNH2 | Q12809 | 2/20 | 0.39 |
| ▸ | RORC | P51449 | 1/20 | 0.39 |
| ▸ | ATM | Q13315 | 1/20 | 0.39 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.38 |
| ▸ | CHRNB2 | P17787 | 1/20 | 0.38 |
| ▸ | CHRNA4 | P43681 | 1/20 | 0.38 |
| ▸ | HTT | P42858 | 1/20 | 0.38 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.36 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL6062434 | 0.84 | AR (0.47) | TSHRL3MBTL1HTR2ASLC6A4KCNH2 | |
| SCHEMBL29960384 | 0.82 | TSHR (0.50) | TSHRNISCHKDM4EL3MBTL1HTR2A | |
| SCHEMBL6680297 | 0.82 | TSHR (0.50) | TSHRNISCHKDM4EL3MBTL1HTR2A | |
| SCHEMBL7710832 | 0.79 | TSHR (0.57) | TSHRNISCHKDM4EL3MBTL1HTR2A | |
| SCHEMBL8693307 | 0.77 | CYP3A4 (0.48) | L3MBTL1CYP3A4CHRNB2CHRNA4HTT | |
| SCHEMBL984038 | 0.76 | TSHR (0.67) | TSHRNISCHKDM4EL3MBTL1RORC | |
| SCHEMBL765607 | 0.75 | HTR2A (0.43) | TSHRNISCHKDM4EL3MBTL1HTR2A | |
| SCHEMBL6061477 | 0.73 | HDAC4 (0.55) | TSHRCASP1ALDH1A1 | |
| SCHEMBL11826075 | 0.73 | LTA4H (0.50) | TSHRCYP3A4ALDH1A1 | |
| SCHEMBL26193516 | 0.73 | AR (0.55) | HTR2ASLC6A4KCNH2ALDH1A1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 15 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| WO-2003002078-A1 | COMPOSITIONS CONTAINING A HYDROXYDIPHENYL ETHER DERIVATIVE INHIBITING BODY ODOURS | L'OREAL (FR) | 2003-01-09 | — | — | WO | claimed |
| WO-2003002080-A1 | COMPOSITIONS CONTAINING A DERIVATIVE OF HYDROXYDIPHENYL ETHER INHIBITING THE DEVELOPMENT OF BODY ODOURS | L'OREAL (FR) | 2003-01-09 | — | — | WO | claimed |
| WO-2003002081-A1 | COMPOSITION COMPRISING A HYDROXYDIPHENYL ETHER DERIVATIVE INHIBITING THE DEVELOPMENT OF BODY ODOURS | L'OREAL (FR) | 2003-01-09 | — | — | WO | claimed |
| WO-2003002072-A1 | COMPOSITIONS CONTAINING A HYDROXYDIPHENYL ETHER DERIVATIVE INHIBITING BODY ODOURS | L'ORÉAL (FR) | 2003-01-09 | — | — | WO | claimed |
| WO-2003002079-A1 | COMPOSITIONS CONTAINING A HYDROXYDIPHENYL ETHER DERIVATIVE INHIBITING BODY ODOURS | L'OREAL (FR) | 2003-01-09 | — | — | WO | claimed |
| EP-1053989-B1 | Hydroxydiphenyl ether compounds | CIBA SC HOLDING AG (CH) | 2007-07-25 | — | — | EP | disclosed |
| US-7105577-B2 | for finishing of undyed and dyed or printed fibre materials; treatment of skin, mucous membrane or hair, hard surfaces, oral care; detergent | CIBA SPECIALTY CHEMICALS CORPORATION (US) | 2006-09-12 | — | — | US | disclosed |
| US-20050203179-A1 | Especially suitable for inhibiting the development of body odour in men | CIBA SPECIALTY CHEMICALS CORP. | 2005-09-15 | — | — | US | disclosed |
| EP-1494640-A1 | USE OF HYDROXYDIPHENYL ETHER DERIVATIVES AS ARYLSULFATASE- INHIBITORS IN DEODORANTS AND ANTIPERSPIRANTS | Ciba SC Holding AG (CH) | 2005-01-12 | — | — | EP | disclosed |
| WO-2003086338-A1 | USE OF HYDROXYDIPHENYL ETHER DERIVATIVES AS ARYLSULFATASE- INHIBITORS IN DEODORANTS AND ANTIPERSPIRANTS | CIBA SPECIALTY CHEMICALS HOLDING INC. (CH) | 2003-10-23 | — | — | WO | disclosed |
| WO-2003002081-A1 | COMPOSITION COMPRISING A HYDROXYDIPHENYL ETHER DERIVATIVE INHIBITING THE DEVELOPMENT OF BODY ODOURS | L'OREAL (FR) | 2003-01-09 | — | — | WO | disclosed |
| WO-2003002080-A1 | COMPOSITIONS CONTAINING A DERIVATIVE OF HYDROXYDIPHENYL ETHER INHIBITING THE DEVELOPMENT OF BODY ODOURS | L'OREAL (FR) | 2003-01-09 | — | — | WO | disclosed |
| WO-2003002078-A1 | COMPOSITIONS CONTAINING A HYDROXYDIPHENYL ETHER DERIVATIVE INHIBITING BODY ODOURS | L'OREAL (FR) | 2003-01-09 | — | — | WO | disclosed |
| WO-2003002072-A1 | COMPOSITIONS CONTAINING A HYDROXYDIPHENYL ETHER DERIVATIVE INHIBITING BODY ODOURS | L'ORÉAL (FR) | 2003-01-09 | — | — | WO | disclosed |
| WO-2003002079-A1 | COMPOSITIONS CONTAINING A HYDROXYDIPHENYL ETHER DERIVATIVE INHIBITING BODY ODOURS | L'OREAL (FR) | 2003-01-09 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20050203179-A1 | Especially suitable for inhibiting the development of body odour in men | SRD5A1, SRD5A2, PON1 | TSHR 1849/4885NISCH 427/4885CASP1 2962/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.